Chemical formula: C₂₃H₂₃N₃O₅ Molecular mass: 421.446 g/mol PubChem compound: 60700
Topotecan is indicated for:
Population group: women, only adults (18 years old or older)
Topotecan monotherapy is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Topotecan is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
